Mibefradil
From Infogalactic: the planetary knowledge core
![]() |
|
Systematic (IUPAC) name | |
---|---|
(1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate
|
|
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a607007 |
Legal status |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Bioavailability | 70 % |
Protein binding | > 99 % |
Metabolism | Hepatic |
Biological half-life | 17-25 h |
Identifiers | |
CAS Number | 116644-53-2 ![]() |
ATC code | C08CX01 (WHO) |
PubChem | CID: 60662 |
IUPHAR/BPS | 2522 |
DrugBank | DB01388 ![]() |
ChemSpider | 54673 ![]() |
UNII | 27B90X776A ![]() |
KEGG | D08217 ![]() |
ChEMBL | CHEMBL45816 ![]() |
Chemical data | |
Formula | C29H38FN3O3 |
Molecular mass | 495.63 g/mol |
|
|
|
|
Physical data | |
Melting point | 128 °C (262 °F) (dihydrochloride salt) |
![]() ![]() |
Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.
It is nonselective.[1]
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. [2]
Synthesis
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html
<templatestyles src="Asbox/styles.css"></templatestyles>